Incyte’s quest for its next big thing ended in disappointment—and a stock tumble—this past week. Unfortunately, the problems ...

What Happened? Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 15.2% in the pre-market session after the company released phase three trial data for a skin condition ...

Shares of Incyte Co. (NASDAQ:INCY – Get Free Report) have been given a consensus recommendation of “Hold” by the nineteen ...

Incyte's revenues continues to grow, with full-year 2024 revenues reaching $4.2 billion, driven by JAKAFI and OPZELURA. Click ...

Shares of Incyte sank Monday, making it the biggest decliner in the S&P 500 after the release of its latest clinical trial.

The stock's fall snapped a four-day winning streak.

Incyte said on Monday its experimental drug has met the main goal in two separate late-stage studies testing it in patients with an inflammatory skin condition called hidradenitis suppurativa.

The website you are visiting is protected and accelerated by Imperva. Your computer may have been infected by malware and ...

Truist lowered the firm’s price target on Incyte (INCY) to $72 from $74 and keeps a Hold rating on the shares. Following the ...

In a report released today, Srikripa Devarakonda from Truist Financial reiterated a Hold rating on Incyte (INCY – Research Report), with a ...

U.S. equities were mixed at midday, with positive news on retail sales eased continuing concerns about tariffs.

These eight projects took top marks in the three office subcategories for this year's Best Real Estate Deals awards program.